medigraphic.com
ISSN 2078-7170 (Electronic)

2019, Number 4

<< Back Next >>

CorSalud 2019; 11 (4)

Biomarkers in heart failure

Jerez CAM

Language: Spanish
References: 28
Page: 317-325
PDF size: 765.18 Kb.


ABSTRACT

Heart failure is an increasingly prevalent disease, which requires additional blood tests that not only confirm what is clinically presumed, but also be useful in the prognostic evaluation of those who suffer from it. In this context, biomarkers with practical utility appeared in the heart failure guidelines, at the beginning of the year 2000. With diagnostic, prognostic and evolutionary indications in each clinical stage of this disease, both in acute and chronic stages, its use draws guidelines and strategies in the adequate treatment of these patients. In this review article, a brief approach to the subject is made.


REFERENCES

  1. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358(20):2148-59.

  2. Rayner-Hartley E, Virani S, Toma M. Update on the management of acute heart failure. Curr Opin Cardiol. 2018;33(2):225-31.

  3. Richards AM. Nuevos biomarcadores en la insu-ficiencia cardiaca: aplicaciones en el diagnóstico, pronóstico y pautas de tratamiento. Rev Esp Car-diol. 2010;63(6):635-9.

  4. Remme WJ, Swedberg K; Task Force for the Di-agnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart fail-ure. Eur Heart J. 2001;22(17):1527-60.

  5. Espinoza Silva C. Biomarcadores en la insuficien-cia cardíaca crónica. Estado del arte [Internet]. En: Espinoza Silva C. Salud Cardiovascular para todos. Valparaíso: Wordpress; 2013 [citado 20 Feb 2019]. Disponible en: https://christianespinoza.wordpress.com/2013/10/20/biomarcadores-en-la-insuficiencia-cardiaca-cronica-estado-del-arte/

  6. Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive sum-mary of the guidelines on the diagnosis and treat-ment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26(4):384-416.

  7. Mallick A, Januzzi JL. Biomarcadores en la insufi-ciencia cardiaca aguda. Rev Esp Cardiol. 2015; 68(6):514-25.

  8. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115(8):949-52.

  9. Pascual Figal DA, Delgado Jiménez JF, Manito Lorite N, Lambert Rodríguez JL, González-Juana-tey JR. Resultados preliminares de una encuesta sobre manejo de la insuficiencia cardiaca aguda en España. Rev Esp Cardiol. 2015;68(Supl 1):994 [Resumen].

  10. D'Alessandro R, Masarone D, Buono A, Gravino R, Rea A, Salerno G, et al. Natriuretic peptides: molecular biology, pathophysiology and clinical implications for the cardiologist. Future Cardiol. 2013;9(4):519-34.

  11. Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: Analytic considerations. Am J Cardiol. 2008; 101(3A):9-15.

  12. Volpe M, Carnovali M, Mastromarino V. The na-triuretic peptides system in the pathophysiology of heart failure: from molecular basis to treat-ment. Clin Sci (Lond). 2016;130(2):57-77.

  13. Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a po-sition statement from the Study Group on Bio-markers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J. 2012;33(16): 2001-6.

  14. Roberts E, Ludman AJ, Dworzynski K, Al-Moha-mmad A, Cowie MR, McMurray JJ, et al. The di-agnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. Version 2. BMJ [Internet]. 2015 [citado 25 Feb 2019];350: h910. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353288

  15. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the di-agnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-200.

  16. Pufulete M, Maishman R, Dabner L, Higgins JP, Rogers CA, Dayer M, et al. B-type natriuretic pep-tide-guided therapy for heart failure (HF): a sys-tematic review and meta-analysis of individual participant data (IPD) and aggregate data. Syst Rev. 2018;7(1):112. Disponible en: https://doi.org/10.1186/s13643-018-0776-8

  17. Bajraktari G, Pugliese NR, D'Agostino A, Rosa GM, Ibrahimi P, Perçuku L, et al. Echo- and B-Type Natriuretic Peptide-Guided Follow-Up versus Symptom-Guided Follow-Up: Comparison of the Outcome in Ambulatory Heart Failure Patients. Cardiol Res Pract [Internet]. 2018 [citado 26 Feb 2019];2018:3139861. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186350/pdf/CRP2018-3139861.pdf

  18. Abuzaanona A, Lanfear D. Pharmacogenomics of the Natriuretic Peptide System in Heart Failure. Curr Heart Fail Rep. 2017;14(6):536-42.

  19. Fudim M, Ambrosy AP, Sun JL, Anstrom KJ, Bart BA, Butler J, et al. High-Sensitivity troponin I in hospitalized and ambulatory patients with heart failure with preserved ejection fraction: Insights from the Heart Failure Clinical Research Network. J Am Heart Assoc [Internet]. 2018 [citado 26 Feb 2019];7(24):e010364. Disponible en: https://www.ahajournals.org/doi/10.1161/JAHA.118.010364

  20. Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompen-sated heart failure. Eur J Heart Fail. 2011;13(7): 718-25.

  21. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA Fo- cused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer-ica. Circulation. 2017;136(6):e137-61.

  22. McCarthy CP, Januzzi JL Jr. Soluble ST2 in Heart Failure. Heart Fail Clin. 2018;14(1):41-8.

  23. Gehlken C, Suthahar N, Meijers WC, de Boer RA. Galectin-3 in Heart Failure: An Update of the Last 3 Years. Heart Fail Clin. 2018;14(1):75-92.

  24. Peacock WF. Novel biomarkers in acute heart fail-ure: MR-pro-adrenomedullin. Clin Chem Lab Med. 2014;52(10):1433-5.

  25. De Berardinis B, Gaggin HK, Magrini L, Belcher A, Zancla B, Femia A, et al. Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal func-tion in patients with acutely decompensated heart failure. Clin Chem Lab Med. 2015;53(4):613-21.

  26. Ozmen C, Deniz A, Deveci OS, Cagliyan CE, Celik AI, Yildiz I, et al. Association among tenascin-C and NT-proBNP levels and arrhythmia preva-lence in heart failure. Clin Invest Med. 2017;40(6): E219-27.

  27. Jungbauer CG, Uecer E, Stadler S, Birner C, Buch-ner S, Maier LS, et al. N-acteyl-ß-D-glucosamini-dase and kidney injury molecule-1: New predic-tors for long-term progression of chronic kidney disease in patients with heart failure. Nephrology (Carlton). 2016;21(6):490-8.

  28. Buonafine M, Martinez-Martinez E, Jaisser F. More than a simple biomarker: the role of NGAL in car-diovascular and renal diseases. Clin Sci (Lond). 2018;132(9):909-23.




2020     |     www.medigraphic.com